Get the Stockscreener App
76.52
5.05%
3.68
After Hours:
76.15
-0.37
-0.48%
Praxis Precision Medicines Inc stock is traded at $76.52, with a volume of 508.28K.
It is up +5.05% in the last 24 hours and up +3.85% over the past month.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.
See More
Previous Close:
$72.84
Open:
$71.25
24h Volume:
508.28K
Relative Volume:
1.56
Market Cap:
$1.43B
Revenue:
$1.77M
Net Income/Loss:
$-123.74M
P/E Ratio:
-25.25
EPS:
-3.03
Net Cash Flow:
$-95.21M
1W Performance:
+9.03%
1M Performance:
+3.85%
6M Performance:
+90.78%
1Y Performance:
+323.00%
1-Day Range:
$71.25
$79.40
1-Week Range:
$68.42
$79.40
52-Week Range:
$18.09
$86.93
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Name
Praxis Precision Medicines Inc
Sector
Industry
Phone
617-300-8460
Address
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
76.52 | 1.43B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-05-24 | Initiated | Oppenheimer | Outperform |
| Jun-24-24 | Initiated | Needham | Buy |
| Jun-18-24 | Initiated | Guggenheim | Buy |
| May-01-24 | Initiated | Robert W. Baird | Outperform |
| Sep-19-23 | Initiated | Truist | Buy |
| Jun-06-22 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Aug-26-21 | Initiated | BofA Securities | Buy |
| Apr-26-21 | Initiated | William Blair | Outperform |
| Nov-11-20 | Initiated | Wedbush | Outperform |
| Nov-10-20 | Initiated | Cowen | Outperform |
| Nov-10-20 | Initiated | Evercore ISI | Outperform |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Praxis Precision Medicines Inc Stock (PRAX) Latest News
Franklin Resources Inc. Grows Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
State Street Corp Has $45.44 Million Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $913,000 Stock Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
(PRAX) Technical Data - Stock Traders Daily
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine - The Bakersfield Californian
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome - GlobeNewswire
Praxis Precision Medicines Secures Key FDA Designation for Promising Epilepsy Drug Relutrigine - StockTitan
Praxis Precision Medicines (NASDAQ:PRAX) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Wellington Management Group LLP Buys 168,394 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Praxis Precision Medicines’ (PRAX) Buy Rating Reiterated at HC Wainwright - Defense World
BNP Paribas Financial Markets Purchases 7,496 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
HC Wainwright Reaffirms "Buy" Rating for Praxis Precision Medicines (NASDAQ:PRAX) - MarketBeat
Expert Ratings For Praxis Precision Medicine - Benzinga
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Bought by Charles Schwab Investment Management Inc. - MarketBeat
Fmr LLC Trims Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Jefferies highlights Praxis Medicines as a 'top idea' for 2025, raises price target - Investing.com
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Where are the Opportunities in (PRAX) - Stock Traders Daily
Jacobs Levy Equity Management Inc. Cuts Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Janus Henderson Group PLC Purchases 141,881 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Praxis Precision management to meet with Oppenheimer - Nasdaq
RA Capital Management L.P. Has $43.84 Million Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
HighVista Strategies LLC Makes New $630,000 Investment in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Praxis Precision Medicines to Present at Upcoming December Investor Conferences - The Manila Times
Praxis Precision Medicines to Present at Major Healthcare Investor Conferences in December - StockTitan
Walleye Capital LLC Buys New Shares in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Baker BROS. Advisors LP Has $18.59 Million Stock Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Fred Alger Management LLC Buys 7,828 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
PRAX (Praxis Precision Medicines) Shares Outstanding (EOP) : 17.79 Mil (As of Sep. 2024) - GuruFocus.com
Verition Fund Management LLC Lowers Stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
PRAX (Praxis Precision Medicines) Debt-to-EBITDA : -0.01 (As of Sep. 2024) - GuruFocus.com
Ally Bridge Group NY LLC Sells 80,194 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Sold by Acuta Capital Partners LLC - MarketBeat
Long Term Trading Analysis for (PRAX) - Stock Traders Daily
Praxis Precision Medicines to Showcase Updates from Largest - GlobeNewswire
Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting - The Manila Times
Why Praxis Precision Medicines Stock Is Trading Higher Tuesday - MSN
Praxis Precision Medicines (NASDAQ:PRAX) Shares Gap Down After Insider Selling - MarketBeat
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Bought by CIBC Asset Management Inc - MarketBeat
Alex Nemiroff Sells 8,239 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Stock - MarketBeat
Insider Selling: Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Insider Sells 5,188 Shares of Stock - MarketBeat
(PRAX) Proactive Strategies - Stock Traders Daily
Praxis Precision Medicines' general counsel sells shares worth $660,827 - Investing.com India
Praxis Precision Medicines principal accounting officer sells $424,318 in stock By Investing.com - Investing.com Australia
Praxis Precision Medicines principal accounting officer sells $424,318 in stock - Investing.com
Praxis Precision Medicines (NASDAQ:PRAX) Trading Down 7.9%Should You Sell? - MarketBeat
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Cormorant Asset Management's Strategic Acquisition in Praxis Pre - GuruFocus.com
Verition Fund Management LLC Adjusts Stake in Praxis Precision M - GuruFocus.com
Capital Research Global Investors Acquires New Stake in Praxis P - GuruFocus.com
What is HC Wainwright's Estimate for PRAX FY2024 Earnings? - MarketBeat
Praxis Precision Medicines Inc Stock (PRAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Praxis Precision Medicines Inc Stock (PRAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nemiroff Alex | General Counsel and Secretary |
Nov 14 '24 |
Sale |
80.20 |
8,239 |
660,827 |
10,301 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 14 '24 |
Option Exercise |
56.94 |
4,374 |
249,056 |
10,801 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 14 '24 |
Sale |
81.78 |
5,188 |
424,318 |
5,613 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):